IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v41y2018i5d10.1007_s40264-017-0636-9.html
   My bibliography  Save this article

Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review

Author

Listed:
  • Martin Braddock

    (AstraZeneca)

  • Nicola A. Hanania

    (Baylor College of Medicine)

  • Amir Sharafkhaneh

    (Baylor College of Medicine
    Michael E. DeBakey VA Medical Center)

  • Gene Colice

    (AstraZeneca)

  • Mats Carlsson

    (AstraZeneca)

Abstract

Introduction Interleukin-13 and interleukin-4 are type-II cytokines signalling through the shared type II interleukin-4 receptor. As a result of their structural similarity, interleukin-13 and interleukin-4 have overlapping functions in the mediation of type-II-driven diseases and are, therefore, promising targets of biologic drugs currently in development for the treatment of such diseases, including asthma and atopic dermatitis. Objective This systematic review was conducted to assess preclinical evidence of potential safety concerns related to blockade of interleukin-13 alone or interleukin-13 and interleukin-4 in combination. Methods We specifically examined risks related to infection, malignancy and the cardiovascular system. We systematically searched the BIOSIS, MEDLINE and EMBASE databases to identify preclinical studies published between January 2006 and October 2016 that addressed the effects of interleukin-13/interleukin-4 blockade and modulation on the risk of infection, malignancy and cardiovascular events. To provide a clinical context, we also performed a search for clinical trials targeting the interleukin-13/interleukin-4 pathways. Relevant data from preclinical and clinical trials were abstracted and presented descriptively. Results Aside from expected evidence that inhibition of interleukin-13 and interleukin-4 impaired host responses to helminth infections, we did not identify other preclinical evidence suggesting safety risks relating to infection, malignancy or cardiovascular events. We found no evidence in clinical trials suggesting serious safety concerns, i.e. increased risk for infections, malignancy or cardiovascular events from therapeutic modulation of the interleukin-13 pathway alone or the combined interleukin-13/interleukin-4 pathways. Conclusions Although our findings are reassuring, long-term safety assessments of biologics that target the interleukin-13/interleukin-4 pathways currently in clinical development are needed.

Suggested Citation

  • Martin Braddock & Nicola A. Hanania & Amir Sharafkhaneh & Gene Colice & Mats Carlsson, 2018. "Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review," Drug Safety, Springer, vol. 41(5), pages 489-509, May.
  • Handle: RePEc:spr:drugsa:v:41:y:2018:i:5:d:10.1007_s40264-017-0636-9
    DOI: 10.1007/s40264-017-0636-9
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-017-0636-9
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40264-017-0636-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:41:y:2018:i:5:d:10.1007_s40264-017-0636-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.